“Provide the best Products for the people”
In 1926, Dr. Ilhan New founded Yuhan Corporation with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Today, Yuhan continues to grow as a global company, with the wellness of people as our first priority.
Research and development (R&D) strategies at Yuhan Research Institute (YRI) are driven, first and foremost, by patient need. This patient-focused approach leads YRI to concentrate on three critical areas of unmet medical need: cardiovascular/metabolic diseases; inflammatory/immune disorders; and oncology. YRI is dedicated to bringing superior treatment options to millions of patients worldwide. To create R&D value, YRI have succeeded in meeting the strategic goal of out-licensing four drugs, amounting to U$ 3 billion until July 2019.
Completed in 2006, our Ochang General Formulations Plant is highly automated and in full compliance with cGMP. It features scalable and flexible production lines and advanced logistics systems, giving Yuhan the capability to bring high-quality medicines to market and to patients efficiently.
Also, Yuhan provides the custom-tailored contract services in research, development, and manufacturing of APIs, key intermediates, and RSMs. Equipped with excellent research capability and cGMP manufacturing facilities with approvals by FDA(US), EDQM(EU), TGA(Australia), PMDA(Japan) and other regulatory agencies, Yuhan develops safe, economical and value-added processes for production and delivery to the global pharmaceutical companies.
Yuhan is prepared to take the lead toward a future filled with new pharmaceutical discoveries and continuing growth. Yuhan will always be with you, our customers and partners, to create a healthier and more prosperous society.
|Sales markets||Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America|
|Affiliated categories:||API Contract Manufacturing |Capsules |Chemical synthesis/analysis More|
CPhI South East Asia 20201 - 3 July 2020 Bangkok, Thailand Visit us at stand P09 Book a meeting See our Exhibitor Profile See full Exhibitor List
Our Top products
Duowell Tab. (Telmisartan · Rosuvastatin)
FDC (Fixed-Dose Combination) tab. of Telmisartan and Rosuvastatin, [Composition] each tablet contains Telmisartan 40mg + Rosuvastatin Ca 5mg, Telmisartan 40mg + Rosuvastatin Ca 10mg, Telmisartan 40mg + Rosuvastatin Ca 20mg, Telmisartan 80mg + Rosuvastatin Ca 5mg, Telmisartan 80mg + Rosuvastatin Ca 10mg, Telmi...More info
Nazacare Nasal Spray
Best choice for allergic rhinitis, [Composition] Each 1mL contains Monetasone Furoate 0.5mg, [Indication] Treatment of nasal symptoms of allergic rhinitis, Treatment of nasal polyps, Acute rhinosinusitis without severe bacterial infection.More info
Anagre (Anagrelide Cap.)
Thrombocytosis treatment, [Compostioon] Each capsult contains Anagrelide 0.5mg, [Indication] Following symptom inprovement of patients with thrombocytosis; Reduction of the elevated platelet count, Reduction of the risk of thrombosis, and Amelioration of associated symptoms including thrombohemorrhagic e...More info
Categories affiliated with Yuhan Corporation
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation